VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CNMD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
CNMDCONMED Corporation
$34.24$1.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

CNMD logoCONMED Corporation(CNMD)Earnings, Financials & Key Ratios

CNMD•NYSE
$35.11
23.3× P/E·Price updated Jul 6, 2026
SectorHealthcareIndustryMedical DevicesSub-IndustrySurgical tools, endoscopy, and robotics
AboutCONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.Show more
  • Revenue$1.37B+5.2%
  • EBITDA$193M-28.9%
  • Net Income$47M-64.5%
  • EPS (Diluted)1.51-64.6%
  • Gross Margin52.77%-5.9%
  • EBITDA Margin14.08%-32.4%
  • Operating Margin10.27%-33.0%
  • Net Margin3.42%-66.2%
  • ROE4.72%-68.0%

CNMD Price & Volume

CONMED Corporation (CNMD) stock price & volume — 10-year historical chart

Loading chart...

Volatile Revenue Growth Masks Structural Margin Risks

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Mixed
Profitability:Strained
Financial:Strained
Cash Flow:Mixed
Primary Risk:High leverage and goodwill

Key Thesis Takeaways

  • CONMED faces a challenging fundamental outlook characterized by inconsistent revenue growth, which contracted 0.7% in 2026Q1, and significant margin volatility that complicates long-term earnings visibility.
  • While the company maintains a presence in surgical technology, its reliance on a $806.9 million goodwill base and a $860.9 million debt load limits strategic flexibility.
  • Investors should monitor whether the company can stabilize its operating margins, which have fluctuated between 3.6% and 20.7%, before committing capital to this highly leveraged medical device player.

Verdict Logic

the company's inconsistent operational performance and high leverage, evidenced by a 18.61 D/EBITDA ratio in 2026Q1, suggest that the current valuation does not adequately compensate for the underlying execution risks.

CNMD Growth Metrics

CONMED Corporation (CNMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years6.69%
5 Years9.77%
3 Years9.55%
TTM4.41%

Profit CAGR

10 Years4.43%
5 Years37.66%
3 Years-
TTM-53.81%

EPS CAGR

10 Years3.31%
5 Years36.38%
3 Years-
TTM-53.37%

Return on Capital

10 Years5.57%
5 Years6.79%
3 Years7.67%
Last Year6.99%

CNMD Recent Earnings

CONMED Corporation (CNMD) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Apr 29, 2026
Metric
Actual
Est
EPS
$0.89+8.5%
$0.82
Rev
$317M+2.1%
$311M
Q1 2026
Jan 28, 2026
Metric
Actual
Est
EPS
$1.43+8.3%
$1.32
Rev
$373M+1.7%
$367M
Q4 2025
Nov 5, 2025
Metric
Actual
Est
EPS
$1.08+2.9%
$1.05
Rev
$338M-7.9%
$367M
Q3 2025
Jul 30, 2025
Metric
Actual
Est
EPS
$1.15+1.8%
$1.13
Rev
$342M+2.3%
$335M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestApr 29, 2026
$0.89vs $0.82+8.5%
$317Mvs $311M+2.1%
Q1 2026Jan 28, 2026
$1.43vs $1.32+8.3%
$373Mvs $367M+1.7%
Q4 2025Nov 5, 2025
$1.08vs $1.05+2.9%
$338Mvs $367M-7.9%
Q3 2025Jul 30, 2025
$1.15vs $1.13+1.8%
$342Mvs $335M+2.3%
Based on last 12 quarters of dataView full earnings history →

Latest CNMD News

Recent stock market news and headlines for CONMED Corporation (CNMD)

Business Wire·5 days ago
CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2026 after the market close on Wednesday, July 29, 2026. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed fro.

Business Wire·Jun 17, 2026
CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of John E. Gallagher as Chief Financial Officer (“CFO”), effective July 15, 2026. Mr. Gallagher succeeds Todd Garner, who remains with the Company in an advisory capacity through November 2, 2026. “We are pleased to welcome a talented and experienced financial executive of John's caliber to CONMED,” said Patrick J. Beyer, CONMED's President and Chief Executive Officer. “John brings deep healthcare and.

Peers Comparison

Key metrics vs top competitors for CONMED Corporation (CNMD)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
CNMD logoCNMDCONMED CorporationCurrent
$35.11$1.08B23.255.16%3.42%4.72%2.26%
HOLX logoHOLXHologic, Inc.
$76.01$16.97B30.531.74%13.18%11.01%—
ATRC logoATRCAtriCure, Inc.
$32.39$1.64B-134.9614.88%-0.83%-0.95%—
NVCR logoNVCRNovoCure Limited
$17.32$1.97B-14.208.28%-25.66%-50.82%—
MMSI logoMMSIMerit Medical Systems, Inc.
$71.45$4.26B33.5411.66%9.03%8.95%—
LMAT logoLMATLeMaitre Vascular, Inc.
$103.72$2.36B41.1613.53%24.35%16.19%—

Compare CNMD vs Peers

CONMED Corporation (CNMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HOLX

Most directly comparable listed peer for CNMD.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare CNMD against a more recognizable public peer.

Peer Set

Compare Top 5

vs HOLX, ATRC, NVCR, MMSI

CNMD SEC Filings & Documents

CONMED Corporation (CNMD) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 29, 2026·SEC

Material company update

Mar 13, 2026·SEC

Material company update

Jan 28, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 17, 2026·SEC

FY 2025

Feb 18, 2025·SEC

FY 2024

Feb 28, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Apr 30, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Jul 31, 2025·SEC

Get notified when CNMD posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

CNMD Frequently Asked Questions

CONMED Corporation (CNMD) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is CONMED Corporation's revenue?

CONMED Corporation (CNMD) reported $1.37B in revenue for fiscal year 2025. This represents a 992% increase from $125.6M in 1996.

How fast is CONMED Corporation growing?

CONMED Corporation (CNMD) grew revenue by 5.2% over the past year. This is steady growth.

Is CNMD profitable?

Yes, CONMED Corporation (CNMD) is profitable, generating $54.8M in net income for fiscal year 2025 (3.4% net margin).

Dividend & Returns
Does CNMD pay dividends?

Yes, CONMED Corporation (CNMD) pays a dividend with a yield of 2.26%. This makes it attractive for income-focused investors.

What is CNMD's return on equity?

CONMED Corporation (CNMD) has a return on equity (ROE) of 4.7%. This is below average, suggesting room for improvement.

What is CONMED Corporation's free cash flow?

CONMED Corporation (CNMD) generated $123.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in CNMD back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →